The FDA approved a supplemental application for Kerendia (finerenone) on September 16, 2026. The application was classified as an efficacy supplement and lists Bayer Healthcare as the sponsor; the supplied record does not identify the specific efficacy claim or any new indication.
Background
The FDA record identifies finerenone by its brand name, Kerendia, and classifies this action as an efficacy supplement to application NDA 215341. The information provided for this event does not describe the drug’s class, mechanism, approved uses before this action, or the condition addressed by the supplement. It also does not provide disease-prevalence information.
What this means
The event records an FDA approval of a supplemental application focused on efficacy, but it does not establish from the supplied details what population, condition, or specific claim the supplement covered. The record does not include clinical trial results, a study design, outcome measurements, or comparisons with another treatment. Those details therefore cannot be used here to characterize the evidence underlying the approval or to determine whether the action changed Kerendia’s indicated use.
Clinicians, researchers, and patient advocates seeking the precise scope of the supplement should consult the FDA application record and associated documents. The available event details identify the application number and sponsor but do not provide further clinical or labeling information. Accordingly, this report describes the recorded regulatory action without inferring a new indication or a change to the drug’s approved population.
Source
Source: U.S. Food and Drug Administration (FDA), Drugs@FDA application overview for NDA 215341, event dated September 16, 2026. Available at accessdata.fda.gov.